SecBot SecBot
8-K ·Filed May 7, 2026

NAMSW

NewAmsterdam Pharma Co N.V.
BULLISH
Impact 6/10
Horizonmonths Processed6mo ago SEC0001193125-26-210283
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The upcoming PREVAIL interim analysis (Q4 2026, result Q1 2027) is a major binary catalyst. Positive outcome could drive significant upside, while failure would severely impact value. Regulatory decisions in 2H26 add further optionality. Monitor for any safety signals or efficacy trends in the interim data.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$22.80
T+0 close · May 7, 2026 · via day close
Latest settled
−34.21%
T+60 · $15.00
Vs SPY
−38.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $22.80entry
  2. T+1 · 6mo ago +22.81%α +21.98% · $28.00
  3. T+5 · 6mo ago +19.78%α +18.28% · $27.31
  4. T+20 · 6mo ago +9.19%α +6.05% · $24.90
  5. T+60 · 4mo ago −34.21%α −38.04% · $15.00

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M (flat YoY) and a net loss of $48.4M, widening from $39.5M. The key catalyst is the planned PREVAIL interim analysis in Q4 2026 with results expected in Q1 2027, plus regulatory decisions in 2H26 for obicetrapib. Cash remains strong at $707.3M.

Key Financial Metrics

Revenue
$3.0M
est $926.0K · +228.3% · +2.1% YoY
Free Cash Flow
-$30.6M

Key Facts

  • Cash, cash equivalents and marketable securities of $707.3M at March 31, 2026
  • Revenue of $3.0M for Q1 2026 (flat vs Q1 2025)
  • Net loss of $48.4M for Q1 2026 vs $39.5M in Q1 2025
  • PREVAIL interim analysis planned for Q4 2026, result expected in Q1 2027
  • Regulatory decisions from EMA, UK, and Switzerland expected in 2H26
  • Completed enrollment in REMBRANDT (323 patients); RUBENS topline data expected year-end 2026

Financial Impact

Net loss increased by $8.9M YoY; cash burn rate ~$21.6M per month in Q1 2026

revenuenet losscash

Risk Factors

  • PREVAIL interim analysis may not show sufficient efficacy for early stopping
  • Regulatory approval in Europe could be delayed or denied
  • Cash burn continues without near-term revenue; need for further financing before PREVAIL readout
  • Competition from existing lipid-lowering therapies

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-210283
Document: nams-20260507.htm0001193125-26-210283
Document: 0001193125-26-210283-index-headers.html0001193125-26-210283
Document: 0001193125-26-210283-index.html0001193125-26-210283
Document: 0001193125-26-210283.txt0001193125-26-210283
8-K Data (Synthetic)0001193125-26-210283

Track record

3 reports on NAMSW

Performance horizon
Filters
  1. Jun 3, 202623w ago 8-K Neutral 3/10 Entry $24.90 to $16.51 Now $9.49 −61.88% ▼ −33.68% −36.18% vs SPY
  2. May 7, 202627w ago 8-K Bullish 6/10 Viewing Entry $22.80 to $15.00 Now $9.49 −58.38% ▼ −34.21% −38.04% vs SPY
  3. Apr 24, 202629w ago 8-K Neutral 3/10 Entry $19.10 to $19.38 Now $9.49 −50.31% ▲ +1.47% −3.31% vs SPY
Showing 3 of 3

US Market Status

Market Closed · Opens in 7h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026